Logo image
A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam
期刊文章   同儕審查

A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam

Kenichiro Maeda, Hironobu Yasui, Tohru Yamamori, Taeko Matsuura, Seishin Takao, Motofumi Suzuki, Akira Matsuda, Osamu Inanami, Hiroki Shirato 和 Fang-Hsin Chen
PloS one, 卷.11(11), 頁.e0166848
22/11/2016
PMID: 27875573
Web of Science ID: WOS:000388886000030

摘要

A549 Cells Animals Antineoplastic Agents - pharmacology Cell Death Cricetinae Cricetulus Cytosine - analogs & derivatives Cytosine - pharmacology DNA Breaks, Double-Stranded - drug effects DNA Breaks, Double-Stranded - radiation effects DNA Repair - drug effects DNA Repair - radiation effects Dose-Response Relationship, Drug Humans Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - therapy Proton Therapy Radiation-Sensitizing Agents - pharmacology Tumor Suppressor Protein p53 - metabolism
The effect of 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd) on proton-induced cell death was evaluated in human lung carcinoma cell line A549 and Chinese hamster fibroblast cell line V79 to enhance relative biological effectiveness (RBE) within the spread-out Bragg peak (SOBP) of proton beams. Treatment with ECyd significantly enhanced the proton-induced loss of clonogenicity and increased senescence at the center, but not at the distal edge of SOBP. The p53-binding protein 1 foci formation assay showed that ECyd decelerated the rate of DNA double-strand break (DSB) repair at the center, but not the distal region of SOBP, suggesting that the ECyd-induced enhancement of proton-induced cell death is partially associated with the inhibition of DSB repair. This study demonstrated that ECyd enhances proton-induced cell killing at all positions of SOBP, except for the distal region and minimizes the site-dependent differences in RBE within SOBP. Thus, ECyd is a unique radiosensitizer for proton therapy that may be useful because it levels the biological dose within SOBP, which improves tumor control and reduces the risk of adverse effects at the distal edge of SOBP.

檔案與連結 (1)

url
https://doi.org/10.1371/journal.pone.0166848檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image